10 Paul Tudor Jones II Halozyme Therapeutics Trades
The first Halozyme Therapeutics trade was made in Q3 2015. Since then Paul Tudor Jones II bought shares three more times and sold shares on six occasions. The investor completely sold their stake between Q4 2020 and Q1 2021.
Avg closing price
Price range
Sold -20.8 Thousand shares
Q1 2021
Avg closing price
$45.65
Price range
$39.51
-
$51.45
Sold 76.7% shares (-68.4 Thousand shares)
Q4 2020
Avg closing price
$35.95
Price range
$25.81
-
$43.62
New holding (+89.2 Thousand shares)
Q3 2020
Avg closing price
$27.85
Price range
$25.74
-
$29.63
Sold -17.4 Thousand shares
Q2 2018
Avg closing price
$18.91
Price range
$16.87
-
$20.30
Sold 43.3% shares (-13.3 Thousand shares)
Q1 2018
Avg closing price
$19.37
Price range
$17.06
-
$21.20
Increased shares by 63.3% (+11.9 Thousand shares)
Q4 2017
Avg closing price
$18.38
Price range
$16.75
-
$20.80
Sold 59.3% shares (-27.3 Thousand shares)
Q3 2017
Avg closing price
$13.54
Price range
$11.76
-
$17.40
New holding (+46.1 Thousand shares)
Q2 2017
Avg closing price
$13.36
Price range
$11.80
-
$14.89
Sold -26.7 Thousand shares
Q4 2015
Avg closing price
$15.94
Price range
$12.93
-
$18.59
New holding (+26.7 Thousand shares)
Q3 2015
Avg closing price
$20.08
Price range
$13.25
-
$24.75
News about Halozyme Therapeutics Inc. and Paul Tudor Jones II
Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche''s OCREVUS® (ocrelizumab) with Halozyme''s ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis | HALO Stock News
SAN DIEGO, July 13, 2023/ PRNewswire/-- Halozyme Therapeutics, Inc. today announced that Roche''s Phase 3 OCARINA II trial
Genentech''s Subcutaneous Formulation Of Tecentriq Shows Positive Results In Phase III Study
(RTTNews) - Roche''s Phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq or atezolizumab with Halozyme''s ENHANZE technology met its...